Abstract
Adenine nucleotides, ADP and ATP, are coreleased from dense granules during platelet activation, as well as from endothelial cells and damaged red blood cells following vascular injury. Through autocrine and paracrine mechanisms, these extracellular signaling molecules interact with the platelet P2 receptors to amplify ongoing platelet activation. Two receptors for ADP, the Gq-protein-coupled P2Y1 and Gi-protein-coupled P2Y12 and one receptor for ATP, the P2X1 ion channel, have been identified on platelets. Due to distinct pharmacological properties and differential regulation, the P2Y and P2X receptors essentially operate on different scales of time and distance and trigger selective intracellular signaling cascades. Recent advances in the understanding of the P2Y receptor physiology have reinforced the concept of these receptors as useful targets for antithrombotic therapy. The function of P2X1 in platelet activation only recently started to be unraveled. This review focuses on recent findings on the physiology of these platelet ADP and ATP receptors, their distinct downstream intracellular signaling pathways as well as on the available agonists, antagonists and inhibitors that allow their pharmacological discrimination.
Keywords: Hemostasis, thrombosis, adenine nucleotides, P2Y1, P2Y12, P2X1, antithrombotic therapy
Current Pharmaceutical Design
Title: The Platelet ATP and ADP Receptors
Volume: 12 Issue: 7
Author(s): C. Oury, E. Toth-Zsamboki, J. Vermylen and M. F. Hoylaerts
Affiliation:
Keywords: Hemostasis, thrombosis, adenine nucleotides, P2Y1, P2Y12, P2X1, antithrombotic therapy
Abstract: Adenine nucleotides, ADP and ATP, are coreleased from dense granules during platelet activation, as well as from endothelial cells and damaged red blood cells following vascular injury. Through autocrine and paracrine mechanisms, these extracellular signaling molecules interact with the platelet P2 receptors to amplify ongoing platelet activation. Two receptors for ADP, the Gq-protein-coupled P2Y1 and Gi-protein-coupled P2Y12 and one receptor for ATP, the P2X1 ion channel, have been identified on platelets. Due to distinct pharmacological properties and differential regulation, the P2Y and P2X receptors essentially operate on different scales of time and distance and trigger selective intracellular signaling cascades. Recent advances in the understanding of the P2Y receptor physiology have reinforced the concept of these receptors as useful targets for antithrombotic therapy. The function of P2X1 in platelet activation only recently started to be unraveled. This review focuses on recent findings on the physiology of these platelet ADP and ATP receptors, their distinct downstream intracellular signaling pathways as well as on the available agonists, antagonists and inhibitors that allow their pharmacological discrimination.
Export Options
About this article
Cite this article as:
Oury C., Toth-Zsamboki E., Vermylen J. and Hoylaerts F. M., The Platelet ATP and ADP Receptors, Current Pharmaceutical Design 2006; 12 (7) . https://dx.doi.org/10.2174/138161206776056029
DOI https://dx.doi.org/10.2174/138161206776056029 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Food-derived bioactive peptides against chronic diseases
Chronic diseases, such as cardiovascular diseases and metabolic diseases, have become a great threat to the human health in recent decades due to the excessive food consumption and the prevalence of sedentary lifestyle. As a class of natural compounds, food-derived bioactive peptides have been demonstrated to possess great potential for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design Gene and Stem Cell Therapy in the Treatment of Erectile Dysfunction and Pulmonary Hypertension; Potential Treatments for the Common Problem of Endothelial Dysfunction
Current Gene Therapy Statins in Peripheral Arterial Disease
Current Pharmaceutical Design New Perspectives in the Pharmacological Potential of Naringin in Medicine
Current Medicinal Chemistry The Therapeutic Potential of ADAM15
Current Pharmaceutical Design Docosahexaenoic Acid-Phosphatidylcholine Improves Cognitive Deficits in an Aβ<sub>23-35</sub>-Induced Alzheimer’s Disease Rat Model
Current Topics in Medicinal Chemistry Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews Myelodysplastic/Myeloproliferative Neoplasms
Current Cancer Therapy Reviews Phentermine and Topiramate Extended-Release for the Obesity: New Kids on the Block
Recent Patents on Cardiovascular Drug Discovery Red Wine Consumption and Prevention of Atherosclerosis: An In Vitro Model Using Human Peripheral Blood Mononuclear Cells
Current Pharmaceutical Design Dendritic Cell-Based Immune Therapy in Liver Diseases
Current Immunology Reviews (Discontinued) Current Trends on Repurposing and Pharmacological Enhancement of Andrographolide
Current Medicinal Chemistry Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents
Recent Patents on CNS Drug Discovery (Discontinued) Recent Research on Medical Stent Manufacturing Based on 3D Printing Technology
Recent Patents on Engineering The Pathophysiological Basis of Renal Nerve Ablation for the Treatment of Hypertension
Current Vascular Pharmacology Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters The Role of Diabetes Mellitus in Sexual and Reproductive Health: An Overview of Pathogenesis, Evaluation, and Management
Current Diabetes Reviews Medicinal Treatments of Cholesterol Gallstones: Old, Current and New Perspectives
Current Medicinal Chemistry Neurodegenerative Disorders and Cholesterol
Current Alzheimer Research